
Bavarian Nordic has announced the initiation of a phase II study with its experimental vaccine MVA-BN RSV against respiratory syncytial virus (RSV). The study follows what the company called “extremely promising results” from a phase I trial announced earlier this year.
The candidate drug is thus following the development path staked out by the biotech in late April when it said the phase II trial in adult patients would be initiated during H2 2016. It plans to follow that up with a phase I pediatric study in early 2017.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app